Fosteabine is an oral and prodrug analogue of cytarabine which is resistant to deoxycytidine deaminase.
[1]. Maloisel F, et al. Results of a phase II trial of a combination of oral cytarabine ocfosfate (YNK01) and interferon alpha-2b for the treatment of chronic myelogenous leukemia patients in chronic phase. Leukemia. 2002 Apr;16(4):573-80.
















